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a b s t r a c t
The dinuclear dichloro complexes [(g6-arene)2Ru2(l-Cl)2Cl2] and [(g5-C5Me5)2M2(l-Cl)2Cl2] react with
2-(pyridine-2-yl)thiazole (pyTz) to afford the cationic complexes [(g6-arene)Ru(pyTz)Cl]+ (arene = C6H6
1, p-iPrC6H4Me 2 or C6Me6 3) and [(g5-C5Me5)M(pyTz)Cl]+ (M = Rh 4 or Ir 5), isolated as the chloride salts.
The reaction of 2 and 3with SnCl2 leads to the dinuclear heterometallic trichlorostannyl derivatives [(g6-
p-iPrC6H4Me)Ru(pyTz)(SnCl3)]+ (6) and [(g6-C6Me6)Ru(pyTz)(SnCl3)]+ (7), respectively, also isolated as
the chloride salts. The molecular structures of 4, 5 and 7 have been established by single-crystal X-ray
structure analyses of the corresponding hexaﬂuorophosphate salts. The in vitro anticancer activities of
the metal complexes on human ovarian cancer cell lines A2780 and A2780cisR (cisplatin-resistant), as
well as their interactions with plasmid DNA and the model protein ubiquitin, have been investigated.
1. Introduction
Organometallic transition metals complexes endowed with
anticancer properties are currently attracting considerable atten-
tion due to their wide and diverse structural types and varied li-
gand bonding modes which offers considerable potential in ﬁne-
tuning their biological properties [1]. Titanocene dichloride was
the ﬁrst organo-transition metal compound to be extensively stud-
ied as an alternative to cisplatin and it underwent numerous clin-
ical evaluations [2]. More recently, targeted ferrocene sandwich
complexes and half-sandwich ruthenium complexes [3] are gain-
ing increasing attention, with encouraging results observed in ani-
mal models [4].
Notably, half-sandwich ruthenium–arene complexes containing
N,N-chelating ligands that are not only of interest in catalysis [5],
are also of interest in bioorganometallic chemistry due to their
anticancer properties [6]. The versatility of the pseudo-tetrahedral
coordination geometry at the metal centre provides considerable
ﬂexibility in terms of rational functionalisation [7]; the aromatic li-
gand provides stability to the metal oxidation state and gives a
lipophilic domain to the complex, while the halide is labile and
usually undergoes hydrolysis in aqueous solution [8] or exchange
with a substrate under catalytic conditions [9] and potentially
physiological conditions. Aquation is believed to be a key aspect
in the biological activity of the [(g6-arene)Ru(en)Cl]+ (en = ethy-
lenediamine) complexes, in which the N,N-chelating ligand en-
dows the complexes with high cytotoxicity towards human
ovarian cancer cells [10]. A structure–activity relationship (SAR)
study showed that the most active complexes contain a coordin-
atively stable N,N-chelating ligand, a hydrophobic arene ligand
and a labile halide group [11]. While osmium arene complexes
have been investigated for their anticancer potential [12] and an
osmium analogue of the [(g6-arene)Ru(en)Cl]+-type complexes
have been studied [10], very few studies of isoelectronic rhodium
and iridium complexes have been undertaken. Nevertheless, rho-
dium half-sandwich compounds containing 1,3,5-triaza-7-phos-
phatricyclo-[3.3.1.1]decanephosphine and chlorido co-ligands
have been evaluated in vitro [6] and model reactions with a series
of nucleosides were also studied [13]. Moreover, Sheldrick and co-
workers have reported a series of related complexes based on rho-
dium and iridium containing N,N-chelating polypyridyl ligands
that are cytotoxic and interact with DNA via coordination, interca-
lation or a combination of both [14]. In general, the results ob-
tained indicate that antiproliferative effects are governed by the
size of the polypyridyl ligands, with the complexes bearing the lar-
ger ligands being more cytotoxic.
In this paper, we describe the synthesis, structural characterisa-
tion and the biological evaluation of a new series of half-sandwich
complexes based on ruthenium, rhodium and iridium incorporat-
ing the coordinatively stable N,N-chelating ligand 2-(pyridine-2-
yl)thiazole (pyTz), a labile chlorido or, in the case of the ruthenium
complexes, a trichlorostannyl group. It was found that all the com-
pounds interact strongly with DNA, but somewhat surprisingly, are
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only slightly cytotoxic. The most cytotoxic compounds are those
containing the trichlorostannyl group.
2. Results and discussion
2.1. Synthesis of the mononuclear complexes 1–7 as chloride salts
The arene or pentamethylcyclopentadienyl complexes [(g6-are-
ne)2Ru2(l-Cl)2Cl2] (arene = C6H6, p-iPrC6H4Me, C6Me6) and [(g5-C5
Me5)2M2(l-Cl)2Cl2] (M = Rh, Ir) react with 2 equiv of 2-(pyridine-2-
yl)thiazole (pyTz) in dichloromethane to form the cationic arene
ruthenium complexes [(g6-C6H6)Ru(pyTz)Cl]+ (1), [(g6-p-iPrC6H4-
Me)Ru(pyTz)Cl]+ (2) and [(g6-C6Me6)Ru(pyTz)Cl]+ (3), and the pen-
tamethylcyclopentadienyl complexes [(g5-C5Me5)Rh(pyTz)Cl]+ (4)
and [(g5-C5Me5)Ir(pyTz)Cl]+ (5), see Scheme 1. All complexes are
isolated as their chloride salts and were characterised by mass
spectrometry, NMR spectroscopy and elemental analysis.
The electrospray ionisation mass spectra of these compounds
show the expected molecular peaks for cations 1–5. In the 1H
NMR spectra of 1–5, the chelating pyTz ligand can be recognised
by characteristic heteroaromatic signals, with the arene or pen-
tamethylcyclopentadienyl ligand giving rise to a singlet for the
methyl proton resonances in the case of 3, 4 and 5, to a singlet
for the protons of the benzene ring in the case of 1 and the typical
para-cymene pattern including the indicative septet in the case of
2 (for further details see Section 3).
Compounds [2]Cl and [3]Cl react with SnCl2 in THF at room tem-
perature to give [(g6-p-iPrC6H4Me)Ru(pyTz)(SnCl3)]Cl ([6]Cl) and
[(g6-C6Me6)Ru(pyTz)(SnCl3)]Cl ([7]Cl), respectively (Scheme 2).
The analogous reaction with [1]Cl, [4]Cl and [5]Cl is hampered by
the limited solubility of these compounds. In the mass spectra of 6
and 7molecular ion peaks are not observed, but fragments that cor-
respond to the loss of SnCl3. However, the 119SnNMRspectra of6 and
7 contain a peak at d = -364.47 for 6 and d = -265.26 ppm for7, indic-
ative of the coordinated SnCl3 unit [15].Moreover, the 1HNMR spec-
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Scheme 1. Synthesis of cations 1–5.
Scheme 2. Synthesis of the cationic trichlorostannyl complexes 6 and 7.
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2.2. Molecular structures of [4]PF6, [5]PF6 and [7]PF6 in the solid state
The molecular structures of cations 4, 5 and 7 have been estab-
lished by single-crystal X-ray structure analysis as their hexa-
ﬂuorophosphate salts, which were obtained by diffusion of a
dichloromethane solution of the corresponding chloride salts
[4]Cl, [5]Cl and [7]Cl in the presence of KPF6 into a diethylether
layer. Salts [4]PF6 and [5]PF6 crystallise in the orthorhombic space
group Pmn21 and [7]PF6 crystallises in the orthorhombic space
group Pnma. The complexes show a typical piano-stool geometry
with the metal centre being coordinated by an arene or pentam-
ethylcyclopentadienyl ring, a chlorido ligand and a chelating
2-(pyridine-2-yl)thiazole ligand. The nitrogen atoms of the 2-(pyr-
idine-2-yl)thiazole ligand are bound to the metal centre and not
the sulfur atom. ORTEP drawings with the atom labelling scheme
for complexes 4 and 5 are shown in Fig. 1, while complex 7 is pre-
sented in Fig. 2. Selected bond lengths and angles for 4, 5 and 7 are
listed in Table 1.
The distance between the metal ion and the centroid of the g5-
C5Me5 ring is shorter in 4 (1.773 Å) than in 5 (1.784 Å), but are
comparable to those in related g5-C5Me5 rhodium and iridium
complexes [5d]. The M–Cl bond lengths are 2.382(2) Å (in 4) and
2.385(4) Å (in 5), which are almost identical to the reported cat-
ionic polypyridyl rhodium complex [(g5-C5Me5)RhCl(40-phenyl-
2,20:60,200-terpyridine)]+ [2.3984(1) Å] [16]. In 7 the Ru–Sn bond
length is comparable to those found in other mononuclear arene
ruthenium trichlorostannyl complexes [15].
In the presence of dichloromethane, compound [7]PF6 crystal-
lises with one molecule of dichloromethane per asymmetric unit
giving rise to multiple intermolecular interactions between the dif-
ferent components of the cell. These intermolecular interactions
are dominated by C–H  F and C–H  Cl contacts. The C  F dis-
tances range from 2.970 to 3.154 Å with angles ranging from
139.3 to 178.8, and the C  Cl distances range from 3.568 to
3.868 Å with angles ranging from 131.7 to 175.9.
2.3. Biological activity of compounds [1–7]Cl
The antiproliferative properties of 1–7 were established by
monitoring their ability to inhibit cell growth using the MTT assay
Fig. 1. ORTEP diagrams of cations 4 (left) and 5 (right) with 50% probability thermal ellipsoids. Hydrogen atoms and counter anions are omitted for clarity. Symmetry code: (i)
1  x, y, z.
Fig. 2. ORTEP diagram of cation 7 with 50% probability thermal ellipsoids.
Hydrogen atoms, dichloromethane solvate and the hexaﬂuorophosphate anion
are omitted for clarity. Symmetry code: (i) x, 1/2  y, z.
Table 1
Selected bond lengths and angles for [4]PF6, [5]PF6 and [7]PF6CH2Cl2.
[4]PF6 [5]PF6 [7]PF6
Interatomic distances
M–N1 2.125(5) 2.070(10) 2.108(4)
M–N2 2.125(5) 2.070(10) 2.108(4)
M–Cl 2.382(2) 2.385(4)
Ru–Sn 2.5952(9)









(see Section 3). Cytotoxic activity was determined on the human
ovarian cancer (A2780) cell line, and its cisplatin-resistant variant
(A2780cisR), after 72 h exposure to the compounds (see Table 2).
All the compounds are less cytotoxic than cisplatin (used as a con-
trol) in both cell lines.
The cytotoxicity of the compounds is low, in the same order of
magnitude as bifunctional ruthenium compounds, that despite
being only weakly active in vitro display good antimetastatic activ-
ity on in vivo models [4a–c]. Indeed, NAMI-A, a ruthenium(III)
coordination complex inactive in vitro, but exhibiting selective
antimetastatic activity in vivo, is now in phase II clinical trials
[17]. However, compared to other organometallic compounds with
N,N-chelating ligands [10,11], 1–7 are signiﬁcantly less cytotoxic.
Indeed, the most active compounds are those containing the tri-
chlorostannyl fragment which is not unexpected since tin com-
pounds are highly cytotoxic [18].
It is tempting to attribute their low cytotoxicity to reduced DNA
interactions due to the absence of either an intercalating group or
good hydrogen bond donors on the N,N-chelating ligand in 1–7. To
test this hypothesis 1–7were incubated with plasmid DNA pBR322
for 12 h at 37 C at different metal: base pair ratios (r = 0.1, 0.05
and 0.01) and the resulting mixtures separated by gel electropho-
resis. A representative gel of pBR322 plasmid treated with 3 in
comparison to cisplatin is shown in Fig. 3. Notably, the migration
and the quantitative distribution of the two most abundant forms
of plasmid DNA (super-coiled and nicked) are affected by the metal
complex similarly to cisplatin, the effects being evident at the
highest metal: base pairs ratios. Similar effects have also been ob-
served for other related compounds [19] and presumably interact
with the DNA via coordination. Since 1–7 damage DNA under these
conditions to a similar degree as cisplatin it seems more likely that
in vitro these compounds do not enter the cell nucleus or mito-
chondria, or are easily detached from the DNA, and therefore do
not interfere with DNA function.
Mass spectrometric approaches have proven potential for the
analysis of metal complex: protein binding [20]. The compounds
were therefore investigated for their ability to bind a model pro-
tein, ubiquitin (Ub), by electrospray ionisation mass spectrometry
(ESI-MS) using established procedures [21]. A comparative analysis
of the intensity of the peaks of the free protein with those of the
adducts provides a qualitative indication of the degree of metalla-
tion. In addition, analysis of the peaks allows identiﬁcation of the
stoichiometry of the adducts and of the nature of protein bound
metallic fragments. Each metal complex was reacted with Ub at
a 3:1 metal:protein molar ratio over 24 h at 37 C. The only com-
pounds that were observed to form adducts with Ub under the gi-
ven conditions are 1, 3 and 4. A representative mass spectrum for 3
(focusing on the +11 and +10 ions) is shown in Fig. 4. The spectrum
contains peaks at 779 (+11 ions) and 857m/z (+10 ions) character-
istic of Ub and additional peaks that are attributed to protein ad-
ducts derived from 3. Notably, the main adduct formed by 3
[peaks at 795 (+11 ions) and 875m/z (+10 ions)] corresponds to
protein species containing a [(g6-C6Me6)Ru]2+ fragment. Addi-
Table 2
IC50a values of [1–7]Cl in the A2780 and A2780cisR cell lines.
Compound IC50 (lM) A2780 IC50 (lM) A2780cisR
Cisplatin 1.6 8.6
[1]Cl >300 >300
[2]Cl 258.3 ± 2.0 214.4 ± 3.3
[3]Cl 182.4 ± 2.6 178.2 ± 2.3
[4]Cl >300 >300
[5]Cl >300 >300
[6]Cl 46.1 ± 0.6 117.8 ± 1.7
[7]Cl 161.9 ± 2.3 124.9 ± 4.3
a IC50 is the drug concentration necessary for 50% inhibition of cell viability.
Fig. 3. Gel showing pBR322 plasmid DNA unmodiﬁed or treated with different
concentrations of cisplatin or [3]Cl (metal complex: DNA base pairs ratio = 0.1, 0.05,
0.01).
Fig. 4. ESI mass spectrum (+11 and +10 ions) of Ub treated with [3]Cl (3:1, metal:protein ratio) in water after 24 h incubation at 37 C.
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tional less intense signals [peaks at 826 (+11 ions) and 909m/z
(+10 ions)] demonstrate the presence of [(g6-C6Me6)Ru(pyTz)]+-
Ub bound metallo-fragments, which presumably form ﬁrst prior
to loss of the N,N-chelating ligand.
In conclusion, a series of organometallic ruthenium, rhodium
and iridium complexes containing 2-(pyridine-2-yl)thiazole as a
co-ligand were prepared and characterised. It was possible to pre-
pare trichlorostannyl adducts of the ruthenium species. All the
compounds were either not cytotoxic or, in the case of the trichlo-
rostannyl derivatives, displayed modest cytotoxicity towards hu-
man ovarian cancer cells. Since all the compounds interact
extensively with DNA, presumably via coordination, and yet dis-
play only modest cytotoxicity, it seems reasonable to conclude that
they do not reach the DNA target in vitro or, if they do reach the
DNA, they must be easily removed by various DNA repair mecha-
nisms [22]. Protein targets have also been implicated in the biolog-
ical role of ruthenium–arene compounds [23] and it would appear
that at least some of the compounds reported herein can bind efﬁ-
ciently to proteins. Such protein interactions presumably play a
role in the mechanism of action of these compounds, in terms of
both cytotoxicity and detoxiﬁcation pathways.
3. Experimental
3.1. General
All reagents were purchased from either Aldrich or Fluka and
used as received. [(g6-arene)2Ru2(l-Cl)2Cl2] [24] and [(g5-
C5Me5)2M2(l-Cl)2Cl2] (M = Rh, Ir) [25] were prepared according
to the literature methods. All manipulations were carried out in
air. The NMR spectra were recorded on a Bruker AvanceII 400 spec-
trometer using the residual protonated solvent as internal stan-
dard. Elemental analyses were performed by the Laboratory of
Pharmaceutical Chemistry, University of Geneva (Switzerland) or
by Mikroelementaranalytisches Laboratorium, ETH Zürich (Swit-
zerland). Electrospray mass spectra were obtained in positive-ion
mode with an LCQ Finnigan mass spectrometer or recorded at
the Department of Chemistry of the University of Fribourg (Swit-
zerland) by Prof. Titus Jenny.
3.2. Preparation of [1]Cl–[3]Cl
To a solution of the dinuclear dichloro complex [(g6-arene)2R-
u2(l-Cl)2Cl2] (0.20 mmol, 100 mg for 1, 122 mg for 2, 133 mg for
3) in CH2Cl2 (30 mL), 65 mg (0.40 mmol) of solid 2-(pyridin-2-
yl)thiazole were added. The resulting mixture was stirred at room
temperature for 16 h. Then the solution was ﬁltered through Celite
in order to remove solid particles, and the solvent was removed
under reduced pressure. The residue was dissolved in methanol
(5 mL), and the product was precipitated by addition of diethyl-
ether (50 mL), isolated by ﬁltration and dried in vacuo.
3.2.1. Spectroscopic data for [(g6-C6H6)Ru(pyTz)Cl]Cl ([1]Cl)
Dark-orange solid, yield 75 mg (91%). 1H NMR (400 MHz,
CD3OD-d4): 6.18 (s, 6H, C6H6), 7.74 (t, 3JH-H = 8 Hz, 1H, C5H4N),
8.23 (m, 2H, C5H4N), 8.30 (d, 1H, 3JH–H = 8 Hz, Tz-H), 8.76 (d, 1H,
3JH–H = 4 Hz, Tz-H), 9.56 (d, 3JH–H = 4 Hz, 1H, C5H4N). 13C{1H} NMR
(100 MHz, CD3OD-d4): 87.66, 125.47, 126.66, 128.64, 129.35,
141.68, 147.24, 152.15, 157.17. Mass (ESI, m/z): 377.1 [MCl]+.
Anal. Calc. for C14H12Cl2N2RuS: C, 40.78; H, 2.93; N, 6.79. Found:
C, 40.98; H, 3.02; N, 6.77 (%).
3.2.2. Spectroscopic data for [(g6-p-iPrC6H4Me)Ru(pyTz)Cl]Cl ([2]Cl)
Orange solid, yield 83 mg (88%). 1H NMR (400 MHz, CD3OD-d4):
1.09 (d, 3JH–H = 8 Hz, 6H, (CH3)2CH), 2.25 (s, 3H, CH3), 2.69 (sept,
3JH–H = 8 Hz, 1H, (CH3)2CH), 5.94 (d, 3JH–H = 8 Hz, 2H, H-Ar), 6.18
(d, 3JH–H = 8 Hz, 2H, H-Ar), 7.76 (t, 3JH–H = 4 Hz, 1H, C5H4N), 8.26
(m, 2H, C5H4N), 8.34 (d, 1H, 3JH–H = 4 Hz, Tz-H), 8.74 (d, 1H, 3JH–H
= 4 Hz, Tz-H), 9.51 (d, 3JH–H = 4 Hz, 1H, C5H4N). 13C{1H} NMR
(100 MHz, CD3OD-d4): 19.06, 22.32, 22.47, 32.47, 84.35, 85.15,
86.77, 86.90, 125.53, 127.19, 128.92, 141.64, 147.33, 157.16. Mass
(ESI, m/z): 433.1 [MCl]+. Anal. Calc. for C18H20Cl2N2RuS: C, 46.15;
H, 4.30; N, 5.98. Found: C, 46.17; H, 4.18; N, 6.83 (%).
3.2.3. Spectroscopic data for [(g6-C6Me6)Ru(pyTz)Cl]Cl ([3]Cl)
Red solid, yield 85 mg (89%). 1HNMR (400 MHz, CD3OD-d4): 2.20
(s, 18H,CH3), 7.78 (t, 3JH–H = 8 Hz, 1H, C5H4N), 8.21 (m,3H,C5H4N, Tz-
H), 8.32 (d, 1H, 3JH–H = 4 Hz, Tz-H), 8.90 (d, 3JH–H = 4 Hz, 1H, C5H4N).
13C{1H} NMR (100 MHz, CD3OD-d4): 16.06, 96.70, 125.08, 127.05,
128.81, 141.24, 144.87, 152.11, 154.77, 166.55. Mass (ESI, m/z):
461.1 [MCl]+. Anal. Calc. for C20H24Cl2N2RuS: C, 48.39; H, 4.87; N,
5.64. Found: C, 48.50; H, 4.99; N, 5.75 (%).
3.3. Preparation of [4]Cl and [5]Cl
To a solution of dinuclear dichloro complex [(g5-C5Me5)2M2(l-
Cl)2Cl2] (0.12 mmol, 74 mg for 4, 100 mg for 5) in CH2Cl2 (30 mL),
41 mg (0.25 mmol) of solid 2-(pyridin-2-yl)thiazole were added.
The resulting mixture was stirred at room temperature for 16 h.
Then, the solution was ﬁltered through Celite in order to remove
solids particles, and the solvent was removed under reduced pres-
sure. The residue was dissolved in methanol (5 mL), and the prod-
uct was precipitated by addition of diethylether (50 mL), isolated
by ﬁltration and dried in vacuo.
3.3.1. Spectroscopic data for [(g5-C5Me5)Rh(pyTz)Cl]Cl ([4]Cl)
Orange solid, yield 49 mg (85%). 1H NMR (400 MHz, CD3OD-d4):
1.79 (s, 15H, CH3), 7.86 (t, 3JH–H = 4 Hz, 1H, C5H4N), 8.29 (m, 3H,
C5H4N, Tz-H), 8.39 (d, 1H, 3JH–H = 4 Hz, Tz-H), 9.01 (d, 3JH–H = 4 Hz,
1H, C5H4N). 13C{1H} NMR (100 MHz, CD3OD-d4): 9.16, 98.68,
125.35, 127.51, 129.55, 141.99, 143.63, 151.42, 153.38, 167.61.Mass
(ESI,m/z): 435.1 [MCl]+. Anal. Calc. for C18H22Cl2N2RhS: C, 45.78;H,
4.70; N, 5.93. Found: C, 45.74; H, 4.75; N, 6.12 (%).
3.3.2. Spectroscopic data for [(g5-C5Me5)Ir(pyTz)Cl]Cl ([5]Cl)
Yellow solid, yield 59 mg (88%). 1H NMR (400 MHz, CD3OD-d4):
1.78 (s, 15H, CH3), 7.83 (t, 3JH–H = 4 Hz, 1H, C5H4N), 8.28 (m, 2H,
C5H4N), 8.31 (d, 1H, 3JH–H = 4 Hz, Tz-H), 8.46 (d, 1H, 3JH–H = 4 Hz,
Tz-H), 9.00 (d, 3JH–H = 4 Hz, 1H, C5H4N). 13C{1H} NMR (100 MHz,
CD3OD-d4): 8.85, 90.73, 125.48, 128.21, 129.98, 141.98, 143.24,
152.36, 153.31, 169.41. Mass (ESI, m/z): 525.1 [MCl]+. Anal. Calc.
for C18H22Cl2IrN2S: C, 38.50; H, 3.95; N, 4.99. Found: C, 38.34; H,
4.02; N, 4.76 (%).
3.4. Preparation of [6]Cl and [7]Cl
To a solution of the mononuclear complexes [(g6-arene)2Ru2(-
pyTz)Cl]Cl (0.20 mmol, 94 mg of [2]Cl, 99 mg of [3]Cl) in THF
(30 mL), 53 mg (0.28 mmol) of solid SnCl2 were added. The result-
ing mixture was stirred at room temperature for 16 h. Then, the
solution was ﬁltered through Celite in order to remove solids par-
ticles, and the solvent was removed under reduced pressure. The
residue was dissolved in methanol (5 mL), and the product was
precipitated by addition of diethylether (50 mL), before being iso-
lated by ﬁltration and dried in vacuo.
3.3.3. Spectroscopic data for [(g6-p-iPrC6H4Me)Ru(pyTz)(SnCl3)]Cl
([6]Cl)
Orange solid, yield 94 mg (72%). 1H NMR (400 MHz, DMSO-d6):
0.98 (d,3JH–H = 8 Hz, 6H, (CH3)2CH), 2.16 (s, 3H, CH3), 2.63 (sept, 3JH–H
= 8 Hz, 1H, (CH3)2CH), 6.03 (d, 3JH–H = 8 Hz, 2H, H-Ar), 6.26 (d, 3JH–H
5
= 8 Hz, 2H, H-Ar), 7.78 (t, 3JH–H = 4 Hz, 1H, C5H4N), 8.25 (t, 3JH–H
= 4 Hz, 1H, C5H4N), 8.43 (d, 1H, 3JH–H = 4 Hz, Tz-H), 8.83 (d, 1H,
3JH–H = 4 Hz, Tz-H), 954 (d, 3JH–H = 4 Hz, 1H, C5H4N). 13C{1H} NMR
(100 MHz, DMSO-d6): 18.26, 21.60, 30.48, 82.75, 83.54, 85.16,
124.37, 126.66, 127.43, 140.43, 146.10, 149.94, 155.87, 164.81.
119Sn NMR (149 MHz, DMSO-d6): 364.47. Mass (ESI, m/z): 433.4
[MSnCl3]+. Anal. Calc. for C18H20Cl4N2RuSSn: C, 32.85; H, 3.06;
N, 4.26. Found: C, 32.91; H, 3.10; N, 4.37 (%).
3.3.4. Spectroscopic data for [(g6-C6Me6)Ru(pyTz)(SnCl3)]Cl ([7]Cl)
Orange solid, yield 99 mg (71%). 1H NMR (400 MHz, DMSO-d6):
2.11 (s, 18H, CH3), 7.79 (t, 3JH–H = 8 Hz, 1H, C5H4N), 8.22 (t, 3JH–H
= 8 Hz, 1H, C5H4N), 8.24 (d, 1H, 3JH–H = 4 Hz, Tz-H), 8.42 (d, 1H,
3JH–H = 4 Hz, Tz-H), 8.96 (d, 3JH–H = 4 Hz, 1H, C5H4N). 13C{1H} NMR
(100 MHz, DMSO-d6): 15.75, 95.09, 124.27, 126.99, 127.91,
140.18, 143.86, 150.37, 153.72, 164.82. 119Sn NMR (149 MHz,
DMSO-d6): 265.26. Mass (ESI, m/z): 461.4 [MSnCl3]+. Anal. Calc.
for C20H24Cl4N2RuSSn: C, 35.01; H, 3.53; N, 4.08. Found: C, 35.15;
H, 3.46; N, 4.22 (%).
3.5. Biological studies
3.5.1. Cell culture and inhibition of cell growth
Human A2780 and A2780cisR ovarian carcinoma cell lines were
obtained from the European Centre of Cell Cultures (ECACC, Salis-
bury, UK) and maintained in culture as described by the provider.
The cells were routinely grown in RPMI 1640 medium containing
10% foetal calf serum (FCS) and antibiotics at 37 C and 6% CO2.
For evaluation of growth inhibition tests, the cells were seeded in
96-well plates (Costar, Integra Biosciences, Cambridge, MA) and
grown for 24 h in complete medium. The stock solutions of metal
complexes were prepared by dissolving the compounds in 1 mL
of DMSO to reach a concentration of 102 M. They were then di-
luted in RPMI medium and added to the wells (100 lL) to obtain
a ﬁnal concentration ranging between 0 and 80 lM. DMSO at com-
parable concentrations did not show any effects on cell cytotoxic-
ity. Complexes stock solutions were diluted directly in culture
medium to the required concentration and added to the cell cul-
ture. After 72 h incubation at 37 C, 20 lL of a solution of MTT
(3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide)
in PBS (2 mg mL1) was added to each well, and the plates were
then incubated for 2 h at 37 C. The medium was then aspirated
and DMSO (100 lL) was added to dissolve the precipitate. The
absorbance of each well was measured at 580 nm using a 96-well
multiwell-plate reader (iEMS Reader MF, Labsystems, Bioconcept,
Switzerland) and compared to the values of control cells incubated
without complexes. The IC50 values for the inhibition of cell growth
were determined by ﬁtting the plot of the percentage of surviving
cells against the drug concentration using a sigmoidal function
(Origin v7.5).
3.5.2. DNA electrophoresis
Samples with pBR322 plasmid DNA were prepared by adding
the required volume of a freshly prepared solution of metal com-
plexes in MilliQ water. The concentration of plasmid in the reac-
tion mixture was 75 ng/L and the concentration of the complexes
was varied to give different metal-to-base pair ratios (0.1, 0.05
and 0.01). The mobility of the metal complex-treated pBR322 sam-
ples was analysed by gel electrophoresis on a 0.8% (w/v) agarose
gel (Boehringer-Mannheim, Mannheim, Germany) at 90 V/cm at
25 C in Tris–acetate/EDTA buffer. The gel was stained for 20 min
in 0.5 g/mL (w/v) ethidium bromide and the bands were analysed
with a UVP gel scanner.
3.5.3. ESI-MS with ubiquitin
Samples were prepared by mixing ubiquitin 100 lM (Sigma,
U6253) with an excess of the appropriate metal complex (3:1,
metal:protein ratio) in MilliQ water (pH 6) and incubated over
24 h at 37 C. Prior to analysis samples were extensively ultraﬁl-
tered using a Centricon YM-3 ﬁlter (Amicon Bioseparations, Milli-
pore Corporation) in order to remove the unbound complex. ESI-
MS data were acquired on a Q-Tof Ultima mass spectrometer
(Waters) ﬁtted with a standard Z-spray ion source and operated
in the positive ionisation mode. Experimental parameters were
set as follows: capillary voltage 3.5 kV, source temperature 80 C,
desolvation temperature 120 C, sample cone voltage 100 V,
desolvation gas ﬂow 400 L/h, acquisition window 300–2000m/z
in 1 s. The samples were diluted 1:10 in water and 5 lL was intro-
duced into the mass spectrometer by infusion at a ﬂow rate of
20 lL/min with a solution of ACN/H2O/HCOOH 50:49.8:0.2
Table 3
Crystallographic and structure reﬁnement parameters for complexes [4]PF6, [5]PF6 and [7]PF6CH2Cl2.
[4]PF6 [5]PF6 [7]PF6CH2Cl2
Chemical formula C18H21ClF6N2PRhS C18H21ClF6N2PIrS C21H26Cl5F6N2PRuSSn
Formula weight 580.76 670.05 880.48
Crystal system Orthorhombic Orthorhombic Orthorhombic
Space group Pmn21 (no. 31) Pmn21 (no. 31) Pnma (no. 62)
Crystal colour and shape Orange block Red block Orange rod
Crystal size 0.24  0.18  0.16 0.19  0.18  0.14 0.23  0.16  0.14
a (Å) 12.763(3) 12.739(3) 23.176(5)
b (Å) 8.123(2) 8.179(2) 13.078(3)
c (Å) 10.531(2) 10.486(2) 10.099(2)
V (Å3) 1091.8(4) 1092.6(4) 3061.0(11)
Z 2 2 4
T (K) 173(2) 173(2) 173(2)
Dcalc (g cm3) 1.767 2.037 1.911
l (mm1) 1.132 6.460 1.919
Scan range () 2.51 < h < 26.16 2.52 < h < 26.14 2.35 < h < 25.61
Unique reﬂections 2237 2129 2828
Reﬂections used [I > 2r(I)] 1944 1981 1894
Flack parameter 0.02(7) 0.02(3)
Rint 0.0430 0.0486 0.0417
Final R indices [I > 2r(I)]* 0.0406, wR2 0.1052 0.0506, wR2 0.1334 0.0350, wR2 0.0696
R indices (all data) 0.0477, wR2 0.1092 0.0542, wR2 0.1408 0.0614, wR2 0.0734
Goodness-of-ﬁt 1.059 1.128 0.860
Max, min Dq (e Å3) 0.768, 0.590 1.439, 4.903 0.923, 0.697
* Structures were reﬁned on Fo2: wR2 = [R[w (Fo2  Fc2)2]/Rw (Fo2)2]1/2, where w1 = [R(Fo2) + (aP)2 + bP] and P = [max(Fo2, 0) + 2Fc2]/3.
6
(v:v:v). External calibration was carried out with a solution of
phosphoric acid at 0.01%. Data were processed using the MassLynx
4.1 software.
3.6. Single-crystal X-ray structure analyses
Crystals of compounds [4]PF6, [5]PF6 and [7]PF6CH2Cl2, pre-
pared by diffusion of a dichloromethane solution of [4]Cl, [5]Cl
and [7]Cl in the presence of KPF6 into a diethylether layer, were
mounted on a Stoe Image Plate Diffraction system equipped with
a / circle goniometer, using Mo Ka graphite monochromated radi-
ation (k = 0.71073 Å) with / range 0–200. The structures were
solved by direct methods using the program SHELXS-97, while the
reﬁnement and all further calculations were carried out using SHEL-
XL-97 [26]. The H-atoms were found on Fourier difference map or
included in calculated positions and treated as riding atoms using
the SHELXL default parameters. The non-H-atoms were reﬁned
anisotropically, using weighted full-matrix least-square on F2.
Crystallographic details are summarised in Table 3. Figs. 1 and 2
were drawn with ORTEP [27].
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